ABSTRACT
BACKGROUND: The surgical treatment of pleural empyema should be carried out depending on the stage of the disease and the patient's symptoms. The aim of this study was to evaluate the outcomes of surgical pleural empyema treatment. PATIENTS AND METHODS: Retrospective analysis of all patients with pleural empyema treated surgically between January 2008 and December 2013. The primary endpoint of the study was inpatient lethality. Secondary endpoints included duration of inpatient stay, type of treatment (surgical/conservative), proof of pathogen and type, alteration and duration of antibiotic therapy. RESULTS: Of 359 patients, 0.8â% (n = 3) had stage I empyema, 50.4â% (n = 181) had stage II and 48.7â% (n = 175) had stage III. The most frequent causes (32.4â%) included acute pneumonia (parapneumonic pleural empyema), surgery (usually thoracic) in 18.0â% of cases and previous pneumonia (postpneumonic pleural empyema) in 15.4â%. Surgery was performed in 86â% of cases (operative procedures: open thoracotomy 85â%, VATS 15â%). The average duration of inpatient stay was 20 days for stages II and III. Recovery following VATS was significantly shorter in stage II compared to thoracotomy (p = 0.022). Hospital lethality amounted to 7.0â% (25 patients). The lethality rate was 5.5â% (10/185) in stage II and 8.6â% (15/175) in stage III. Patients with confirmed pathogens had a significantly worse mortality rate across all stages (9.8â%) than patients with no confirmed pathogens (4.0â%, p = 0.034). Age, malignant underlying disease, multiple comorbidities, immunosuppression, a change in antibiotic regimens and sepsis were significant risk factors. CONCLUSION: The inpatient lethality of patients with pleural empyema correlates with the stage of the condition. Positive confirmation of pathogens, sepsis, a higher age, multiple comorbidities, malignant tumour disease, immunosuppression and a change of antibiotics are negative prognostic factors.
Subject(s)
Bacterial Infections/classification , Bacterial Infections/surgery , Empyema, Pleural/classification , Empyema, Pleural/surgery , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/mortality , Combined Modality Therapy , Empyema, Pleural/mortality , Female , Germany , Hospital Mortality , Humans , Length of Stay , Male , Middle Aged , Pneumonectomy/methods , Retrospective Studies , Risk Factors , Thoracentesis/methods , Thoracic Surgery, Video-Assisted/methods , Thoracotomy/methodsABSTRACT
INTRODUCTION: Parapneumonic pleural effusions arise from pneumonia and may develop into pleural empyema (PE). PE is defined as collection of pus in the pleural space with secondary inflammation of the visceral and parietal pleura. This review article describes the current treatment strategies for para- and postpneumonic PE both in children and adults. MATERIAL AND METHODS: Selective literature research via Medline (key words: pleural empyema, pleural empyema in children, thoracic empyema) and presentation of our own clinical experience with therapy recommendations. RESULTS: The incidence of postpneumonic PE is increasing in both children and adults. PE is associated with a high morbidity and mortality if it is not treated early and adequate. Progression of PE follows a characteristic morphological course, which is classified in three stages: the exsudative, fibrinopurulent, and organizing phase. Treatment should be adapted to these three phases including systemic antibiotic therapy and drainage of the pleural space. Intrapleural fibrinolysis can be performed with good success independent of age in the transition of stage 1 and 2. In persistent PE (stage 2), thoracoscopic decortication is recommended to avoid progression into the organizing phase (stage 3) with the need of an open decortication. In debilitated elderly patients the increasing use of intrathoracic vacuum therapy (Mini-VAC/Mini-VAC-instill) offers an effective and less invasive therapy option. CONCLUSION: Para- and postpneumonic PE requires an individualized and stage adapted therapy using a combination of medical and surgical treatment strategies with the aims of removing the source of infection and ensuring re-establishment of lung expansion.